末梢血単核細胞（PBMC）の世界市場の評価：製品別、用途別、技術別、由来別、地域別、機会、予測（2016年～2030年）

世界の末梢血単核細胞（PBMC）の市場規模は、2022年の5億8,984万米ドルから2030年までに2億7,328万米ドルに達し、2023年～2030年の予測期間にCAGRで10.09%の成長が予測されています。免疫力を高めるため、また体内のさまざまな生物学的・病理学的プロセスを理解するための抗体の開発に向けたPBMCに対する需要の高まりなどの要因が、市場の成長に寄与しています。

当レポートでは、世界の末梢血単核細胞（PBMC）市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 COVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界の末梢血単核細胞（PBMC）市場の見通し（2016年～2030年）

• 市場規模と予測
  • 金額
• 製品別
  • 凍結保存PBMC
  • 培養または新鮮なPBMC
  • 末梢血単核細胞（PBMC）分離・生存率キット
  • その他
• 用途別
  • 免疫学
  • 血液学
  • ワクチン開発
  • 毒物学
  • 感染症
  • その他
• 技術別
  • 密度勾配遠心分離
  • 白血球除去療法
  • その他
• 由来別
  • 人間
  • 動物
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 市場シェア：企業別（2022年）

第6章 世界の末梢血単核細胞（PBMC）市場の見通し：地域別（2016年～2030年）

• 北米
  • 製品別
  • 用途別
  • 技術別
  • 由来別
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • スペイン
• 南米
  • ブラジル
  • アルゼンチン
  • コロンビア
• アジア太平洋
  • インド
  • 中国
  • 日本
  • オーストラリア
  • シンガポール
  • 韓国
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第7章 市場マッピング（2022年）

• 製品別
• 用途別
• 技術別
• 由来別
• 地域別

第8章 マクロ環境と業界構造

• 需給の分析
• 輸出入の分析 - 数量と金額
• サプライ/バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第9章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第10章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• FDAの承認
• イノベーション/最新技術

第11章 主要企業情勢

• マーケットリーダー上位5社の競合マトリックス
• マーケットリーダー上位5社の市場の収益分析（2022年）
• 合併と買収/合弁事業（該当する場合）
• SWOT分析（市場参入企業5社向け）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

• Corning Inc
• Lonza Group AG
• Charles River Laboratories International, Inc.
• Bio-Rad Laboratories Inc
• ABCAM
• iXCells Biotechnologies USA, LLC
• ZEN-Bio Inc
• StemExpress, LLC
• Ray Biotech Life, Inc.
• Biopredic International
• Precision Medicine Group, LLC.

第15章 戦略的推奨事項

第16章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 2. Global Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 3. Global Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 4. Global Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 5. Global Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 6. Global Peripheral Blood Mononuclear Cells Market Share, By Region, in USD Million, 2016-2030F
• Figure 7. North America Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 8. North America Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 9. North America Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 10. North America Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 11. North America Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 12. North America Peripheral Blood Mononuclear Cells Market Share, By Country, in USD Million, 2016-2030F
• Figure 13. United States Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 14. United States Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 15. United States Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 16. United States Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 17. United States Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 18. Canada Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 19. Canada Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 20. Canada Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 21. Canada Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 22. Canada Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 23. Mexico Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 24. Mexico Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 25. Mexico Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 26. Mexico Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 27. Mexico Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 28. Europe Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 29. Europe Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 30. Europe Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 31. Europe Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 32. Europe Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 33. Europe Peripheral Blood Mononuclear Cells Market Share, By Country, in USD Million, 2016-2030F
• Figure 34. Germany Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 35. Germany Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 36. Germany Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 37. Germany Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 38. Germany Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 39. France Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 40. France Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 41. France Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 42. France Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 43. France Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 44. Italy Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 45. Italy Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 46. Italy Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 47. Italy Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 48. Italy Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 49. United Kingdom Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 50. United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 51. United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 52. United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 53. United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 54. Spain Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 55. Spain Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 56. Spain Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 57. Spain Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 58. Spain Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 59. South America Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 60. South America Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 61. South America Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 62. South America Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 63. South America Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 64. South America Peripheral Blood Mononuclear Cells Market Share, By Country, in USD Million, 2016-2030F
• Figure 65. Brazil Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 66. Brazil Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 67. Brazil Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 68. Brazil Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 69. Brazil Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 70. Argentina Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 71. Argentina Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 72. Argentina Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 73. Argentina Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 74. Argentina Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 75. Colombia Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 76. Colombia Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 77. Colombia Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 78. Colombia Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 79. Colombia Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 80. Asia-Pacific Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 81. Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 82. Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 83. Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 84. Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 85. Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Country, in USD Million, 2016-2030F
• Figure 86. India Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 87. India Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 88. India Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 89. India Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 90. India Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 91. China Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 92. China Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 93. China Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 94. China Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 95. China Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 96. Japan Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 97. Japan Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 98. Japan Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 99. Japan Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 100. Japan Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 101. Australia Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 102. Australia Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 103. Australia Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 104. Australia Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 105. Australia Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 106. South Korea Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 107. South Korea Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 108. South Korea Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 109. South Korea Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 110. South Korea Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 111. Singapore Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 112. Singapore Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 113. Singapore Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 114. Singapore Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 115. Singapore Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 116. Middle East & Africa Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 117. Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 118. Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 119. Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 120. Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 121. Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Country, in USD Million, 2016-2030F
• Figure 122. Saudi Arabia Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 123. Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 124. Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 125. Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 126. Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 127. UAE Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 128. UAE Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 129. UAE Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 130. UAE Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 131. UAE Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 132. South Africa Peripheral Blood Mononuclear Cells Market, By Value, in USD Million, 2016-2030F
• Figure 133. South Africa Peripheral Blood Mononuclear Cells Market Share, By Product, in USD Million, 2016-2030F
• Figure 134. South Africa Peripheral Blood Mononuclear Cells Market Share, By Application, in USD Million, 2016-2030F
• Figure 135. South Africa Peripheral Blood Mononuclear Cells Market Share, By Techniques, in USD Million, 2016-2030F
• Figure 136. South Africa Peripheral Blood Mononuclear Cells Market Share, By Source, in USD Million, 2016-2030F
• Figure 137. By Product Map-Market Size (USD Million) & Growth Rate (%), 2022
• Figure 138. By Application Map-Market Size (USD Million) & Growth Rate (%), 2022
• Figure 139. By Techniques Map-Market Size (USD Million) & Growth Rate (%), 2022
• Figure 140. By Source Map-Market Size (USD Million) & Growth Rate (%), 2022
• Figure 141. By Region Map-Market Size (USD Million) & Growth Rate (%), 2022

The Global Peripheral Blood Mononuclear Cells (PBMCs) Market is projected to reach USD 273.28 million by 2030 from USD 589.84 million in 2022, growing at a CAGR of 10.09% for the forecast period between 2023 and 2030. Multiple factors are contributing to the growth of the global peripheral blood mononuclear cells market such as the growing demand for PBMCs for antibody development to enhance immunity and comprehend various biological and pathological processes in the body.

Additionally, PBMCs are widely used in clinical research studies related to immunology as these cells are a mixture of different immune cell types, including lymphocytes (T cells and B cells) and monocytes. By studying PBMCs, researchers can gain insights into the functioning of the immune system as a whole and understand how different immune cell populations interact and respond to various stimuli. Apart from this, PBMCs are easily available, accessible at low cost to facilitate research. Owing to this, the demand for PBMCs among researchers and scientists is high and are the prime end-users of these cells.

Researchers in academic institutions, pharmaceutical companies, biotechnology firms, and other research organizations are the primary end users of PBMCs. They require PBMCs to investigate various aspects of immunology, infectious diseases, autoimmune disorders, transplantation, vaccine development, and other areas of biomedical research. Thus, the expansion of research and development programs launched by various governments and commercial organizations throughout the world is augmenting the demand for PBMC, resulting in driving the market growth.

Increasing Use of PBMCs for Cell Therapy:

Cell therapy has gained significant attention from investors, pharmaceutical companies, and biotechnology firms. There has been a substantial increase in funding for research and development in the field of cell therapies, which has accelerated the translation of promising preclinical and clinical findings into viable treatments. Moreover, North America and Europe have aging populations facing a higher prevalence of chronic and age-related diseases. Cell therapy holds great promise in addressing some of these unmet medical needs. As traditional treatment options fall short in providing effective solutions, patients, healthcare providers, and policymakers are increasingly looking towards cell-based therapies as a potential means of delivering transformative outcomes.

Additionally, PBMCs are used to assess immune responses in both preclinical and clinical stages of cell therapy development. Researchers may collect PBMCs from patients before and after treatment to evaluate changes in immune cell populations, cytokine production, or other immune parameters.

Increase in R&D:

As novel cell/gene therapies/medications and new products are being developed for the treatment of fatal diseases, R&D, clinical trials, and other activities are advancing at a rapid rate, driving the market's growth. PBMCs simplify the process of drawing blood samples for physiologically relevant proteins, without the analytical challenges of native human plasma originating from the presence of highly abundant proteins. Governments around the globe are also investing heavily in peripheral blood mononuclear cells. The number of publications made on PBCMs in clinical research has accelerated over the last 10 years by twofold.

Growing Rate of Toxicology Research:

Two key growth factors for the market's expansion are consumers' rising need for peripheral blood mononuclear cells and their rising preference for antibody development. To comprehend the biological and pathological processes, as well as in clinical research, research on fatal illnesses, immunology, vaccine creation, etc., PBMC cell investigation is essential. The impacts of potential new drug compounds on humans, particularly on their immune systems, are shown by PBMCs. Immune system suppression and poisoning are only a couple of the major, occasionally deadly toxic side effects of drug toxicity that affects PBMCs.

Advancement with Peripheral Blood Mononuclear Cells:

PBMCs are a source of cells to promote osteochondral lesions' recovery. One of the benefits of PBMC treatment is that, unlike other sources of multipotent cells, peripheral blood cell separation is less invasive and isn't needed for general anesthetic. BioIVT, a renowned company specializing in research models and services for the advancement of drugs and diagnostics, has revealed its collaboration with Promega Corporation. The collaboration involves BioIVT supplying peripheral blood mononuclear cells (PBMCs) for Promega's latest PBMC Antibody-Dependent Cellular Cytotoxicity (ADCC) Bioassay. This innovative bioassay employs PBMCs to replicate in vivo scenarios and evaluate the ADCC capabilities of antibodies during the process of drug development and characterization.

The PBMC ADCC Bioassay, in conjunction with Promega technologies, introduces a pioneering kit that includes PBMCs qualified for ADCC assessments. The kit is designed with a user-friendly add-mix-read process and a highly sensitive luminescent readout, ensuring a reliable range for assay results. With multiple assay formats available, the kit offers ADCC-qualified PBMC effector cells and allows the selection of target cells expressing a HiBiT fusion protein, catering to different preferences. When target cells are eliminated, a vivid luminescent signal is produced, indicating successful killing.

Impact of COVID-19:

The COVID-19 pandemic caused significant disruption to the peripheral mononuclear blood cells industry. Peripheral mononuclear blood cells are a critical component of the immune system and are used in a variety of research applications, including drug discovery and vaccine development. With the outbreak of COVID-19, there has been a surge in demand for PBMCs from researchers working to develop treatments and vaccines for the virus. This has led to a shortage of PBMCs and an increase in their cost. Additionally, the pandemic has disrupted supply chains, causing delays in the transportation and processing of PBMCs. The closure of research labs and universities due to lockdowns and social distancing measures has also reduced the demand for PBMCs in non-COVID research, further impacting the market.

Key Players Landscape and Outlook:

As per the findings of a clinical trial conducted at the University of Colorado Cancer Centre, a microfluidic squeezing technology used on PBMCs aids in stimulating anti-tumor activity in a subtype of HPV16-positive cancers (such as head, neck, cervical, and anal cancers), thus speeding up the process.

In 2022, Purigen Biosystems launched ionic cells to pure DNA kits for white blood cell and peripheral mononuclear cell control samples. The new kit has been optimized to extract higher yields of high-quality DNA from white blood cells, peripheral blood mononuclear cells, and cultured or sorted cells.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Executive Summary

5. Global Peripheral Blood Mononuclear Cells Market Outlook, 2016-2030F

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. By Product
  • 5.2.1. Cryopreserved or Frozen PBMC
  • 5.2.2. Culture or Fresh PBMC
  • 5.2.3. Peripheral Blood Mononuclear Cell Isolation & Viability Kits
  • 5.2.4. Others
• 5.3. By Application
  • 5.3.1. Immunology
  • 5.3.2. Haematology
  • 5.3.3. Vaccine Development
  • 5.3.4. Toxicology
  • 5.3.5. Infectious Disease
  • 5.3.6. Others
• 5.4. By Techniques
  • 5.4.1. Density Gradient Centrifugation
  • 5.4.2. Leukapheresis
  • 5.4.3. Others
• 5.5. By Sources
  • 5.5.1. Human
  • 5.5.2. Animal
• 5.6. By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. South America
  • 5.6.4. Asia-Pacific
  • 5.6.5. Middle East and Africa
• 5.7. By Company Market Share (%), 2022

6. Global Peripheral Blood Mononuclear Cells Market Outlook, By Region, 2016-2030F

• 6.1. North America*
  • 6.1.1. By Product
    • 6.1.1.1. Cryopreserved or Frozen PBMC
    • 6.1.1.2. Culture or Fresh PBMC
    • 6.1.1.3. Peripheral Blood Mononuclear Cell Isolation & Viability Kits
    • 6.1.1.4. Others
  • 6.1.2. By Application
    • 6.1.2.1. Immunology
    • 6.1.2.2. Haematology
    • 6.1.2.3. Vaccine Development
    • 6.1.2.4. Toxicology
    • 6.1.2.5. Infectious Disease
    • 6.1.2.6. Others
  • 6.1.3. By Techniques
    • 6.1.3.1. Density Gradient Centrifugation
    • 6.1.3.2. Leukapheresis
    • 6.1.3.3. Others
  • 6.1.4. By Sources
    • 6.1.4.1. Human
    • 6.1.4.2. Animal
  • 6.1.5. United States*
    • 6.1.5.1. By Product
    • 6.1.5.1.1. Cryopreserved or Frozen PBMC
    • 6.1.5.1.2. Culture or Fresh PBMC
    • 6.1.5.1.3. Peripheral Blood Mononuclear Cell Isolation & Viability Kits
    • 6.1.5.1.4. Others
    • 6.1.5.2. By Application
    • 6.1.5.2.1. Immunology
    • 6.1.5.2.2. Hematology
    • 6.1.5.2.3. Infectious Disease
    • 6.1.5.2.4. Others
    • 6.1.5.3. By Techniques
    • 6.1.5.3.1. Density Gradient Centrifugation
    • 6.1.5.3.2. Leukapheresis
    • 6.1.5.3.3. Others
    • 6.1.5.4. By Sources
    • 6.1.5.4.1. Human
    • 6.1.5.4.2. Animal
  • 6.1.6. Canada
  • 6.1.7. Mexico

All segments will be provided for all regions and countries covered

• 6.2. Europe
  • 6.2.1. Germany
  • 6.2.2. France
  • 6.2.3. Italy
  • 6.2.4. United Kingdom
  • 6.2.5. Spain
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
  • 6.3.3. Colombia
• 6.4. Asia-Pacific
  • 6.4.1. India
  • 6.4.2. China
  • 6.4.3. Japan
  • 6.4.4. Australia
  • 6.4.5. Singapore
  • 6.4.6. South Korea
• 6.5. Middle East & Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. South Africa

7. Market Mapping, 2022

• 7.1. By Product
• 7.2. By Application
• 7.3. By Techniques
• 7.4. By Source
• 7.5. By Region

8. Macro Environment and Industry Structure

• 8.1. Supply Demand Analysis
• 8.2. Import Export Analysis - Volume and Value
• 8.3. Supply/Value Chain Analysis
• 8.4. PESTEL Analysis
  • 8.4.1. Political Factors
  • 8.4.2. Economic System
  • 8.4.3. Social Implications
  • 8.4.4. Technological Advancements
  • 8.4.5. Environmental Impacts
  • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 8.5. Porter's Five Forces Analysis
  • 8.5.1. Supplier Power
  • 8.5.2. Buyer Power
  • 8.5.3. Substitution Threat
  • 8.5.4. Threat from New Entrant
  • 8.5.5. Competitive Rivalry

9. Market Dynamics

• 9.1. Growth Drivers
• 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

• 10.1. Clinical Trials
• 10.2. Patent Landscape
• 10.3. FDA Approvals
• 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. Corning Inc
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Key Market Focus & Geographical Presence
  • 14.1.6. Recent Developments
• 14.2. Lonza Group AG
• 14.3. Charles River Laboratories International, Inc.
• 14.4. Bio-Rad Laboratories Inc
• 14.5. ABCAM
• 14.6. iXCells Biotechnologies USA, LLC
• 14.7. ZEN-Bio Inc
• 14.8. StemExpress, LLC
• 14.9. Ray Biotech Life, Inc.
• 14.10. Biopredic International
• 14.11. Precision Medicine Group, LLC.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15. Strategic Recommendations

16. About Us & Disclaimer